bioAffinity Technologies, Inc. Common Stock (BIAF)

About bioAffinity Technologies, Inc. Common Stock

bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.

Institutional ownership

In 13F filings for the quarter ended June 30, 2026, 18 institutions reported holding BIAF, with 795,494 shares worth $774,035 in aggregate. The largest reported holder was Sabby Management, with 365,647 shares worth $296,905. Of the 5 largest holders listed below, 2 opened new positions in BIAF, 1 added shares and 2 held their positions unchanged during the quarter.

Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.

Frequently asked questions